|
Title
|
Pleiotropic effects of statins: A focus on cancer
|
|
Type
|
JournalPaper
|
|
Keywords
|
Mevalonate cascade Prenylation Apoptosis Cancer therapy Autophagy Chemotherapy
|
|
Abstract
|
The statin drugs (‘statins’) potently inhibit hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase by com- petitively blocking the active site of the enzyme. Statins decrease de novo cholesterol biosynthesis and thereby reduce plasma cholesterol levels. Statins exhibit “pleiotropic” properties that are independent of their lipid- lowering effects. For example, preclinical evidence suggests that statins inhibit tumor growth and induce apoptosis in specific cancer cell types. Furthermore, statins show chemo-sensitizing effects by impairing Ras family GTPase signaling. However, whether statins have clinically meaningful anti-cancer effects remains an area of active investigation. Both preclinical and clinical studies on the potential mechanisms of action of statins in several cancers have been reviewed in the literature. Considering the contradictory data on their efficacy, we present an up-to-date summary of the pleiotropic effects of statins in cancer therapy and review their impact on different malignancies. We also discuss the synergistic anti-cancer effects of statins when combined with other more conventional anti-cancer drugs to highlight areas of potential therapeutic development.
|
|
Researchers
|
Tayyebeh Madrakian (Not In First Six Researchers), Saeid Ghavami (Not In First Six Researchers), Jakub Rosik (Fifth Researcher), Filip Machaj (Fourth Researcher), Stevan Pecic (Third Researcher), Shayan Amiri (Second Researcher), Mazaher Ahmadi (First Researcher)
|